

**Amendments to the Claims:** This listing of claims will replace all prior versions, and listings, of claims in the application

**Listing of Claims:**

1. - 54. (Canceled)

55. (Currently Amended) An isolated recombinant polypeptide comprising a member selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2, or and
- (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids having an aligned contiguous segment from amino acid positions 1-47 or amino acid positions 104-276 of SEQ ID NO:2,

~~fragment of at least 40 contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment isolated polypeptide, when administered to a subject in a composition which can include an adjuvant, or conjugated to a suitable carrier, induces an antibody or T-cell immune response that recognizes the~~ to the polypeptide sequence of SEQ ID NO:2.

56. (Currently Amended) The isolated recombinant polypeptide of claim 55, wherein the polypeptide comprises the amino acid sequence SEQ ID NO:2.

57. (Currently Amended) The isolated recombinant polypeptide of claim 55, wherein the polypeptide consists of the amino acid sequence SEQ ID NO:2.

58. (Currently Amended) The isolated recombinant polypeptide of claim 55, wherein the polypeptide comprises an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids having an aligned contiguous segment from amino acid positions 1-47 or amino acid positions 104-276 of SEQ ID NO:2~~an immunogenic fragment of at least 40 contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a composition which can include an adjuvant, or conjugated to a suitable carrier, induces an antibody or T cell immune response that recognizes the polypeptide~~ SEQ ID NO:2.

59. (Currently Amended) An isolated recombinant fusion protein comprising the isolated recombinant polypeptide of claim 55.

- 60. (Currently Amended) An isolated recombinant fusion protein comprising the isolated recombinant polypeptide of claim 56.
- 61. (Previously Presented) An isolated recombinant fusion protein comprising the polypeptide of claim 58.
- 62. (Currently Amended) An immunogenic composition comprising the isolated recombinant polypeptide of claim 55.
- 63. (Previously Presented) An immunogenic composition comprising the isolated recombinant fusion protein of claim 59.
- 64. (Currently Amended) A vaccine comprising the isolated recombinant polypeptide of claim 55 and a pharmaceutically acceptable carrier.
- 65. (Currently Amended) A vaccine comprising the isolated recombinant polypeptide of claim 56 and a pharmaceutically acceptable carrier.
- 66. (Currently Amended) A vaccine comprising the isolated recombinant polypeptide of claim 58 and a pharmaceutically acceptable carrier.
- 67. (Previously Presented) The vaccine according to claims 64, 65, or 66, further comprising at least one other *Moraxella catarrhalis* antigen.
- 68. (Previously presented) A method for inducing an immune response in a mammal comprising administration of the isolated recombinant polypeptide of claim 55.